Incyte Corporation

Bristol-myers Squibb Compnay

Incyte Holdings Corporation

Peggy Ann Scherle

Krishna Vaddi

Steven M Friedman

Jordan S Fridman

Xuesong Liu

Xiangdong Liu

Percy H Carter

Timothy C Burn

Gregory Franklin Hollis

Robert Newton

Kimberly A Solomon

Qihong Zhao

Reid Huber

Phillip C C Liu

Joseph E Dinchuk

Paul Davies

This invention relates to methods of treating B-cell malignancies using a combination of inhibitors of JAK1 and/or JAK2 and inhibitors of PI3K&#x3b4;.

Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors

The present invention relates to compositions, methods and kits based on the ADAM-mediated cleavage of Her-2. The present invention also relates to treatments for cancer, and in particular, breast cancer, by modulating the ADAM-mediated cleavage of Her-2. Further, the invention relates to compositions, methods and kits based on the surprising synergistic effect between inhibition of Her-2 cleavage by an ADAM and certain cytostatic (e.g., Herceptin) and cytotoxic (e.g., Taxol) compounds in, among other things, inhibiting tumor cell proliferation and inducing cell death. Additionally, the invention relates to novel variants of ADAM15, designated ADAM15 variant 1 and ADAM15 variant 2, now identified and isolated.

Compositions, methods and kits relating to HER-2 cleavage

Compositions, methods and kits relating to Her-2 cleavage

The present invention is directed to pharmaceutical methods for the treatment of CD30 positive diseases, such as Hodgkin's disease, by administration of a combination of at least one sheddase inhibitor and at least one anti-CD30 immunotherapeutic.

Sheddase inhibitors combined with CD30-binding immunotherapeutics for the treatment of CD30 positive diseases

The present invention relates to a chimeric chemokine receptor comprising two components: a first sequence comprising the N terminus through the last residue of the seven helix TM region of a first chemokine receptor joined with a second sequence comprising the C terminus of a second chemokine receptor extending from the first intracellular residue of the chemokine receptor to the last residue of the chemokine receptor. The chimeric chemokine receptor can be employed in various applications, such as ligand binding and screening assays and signalling assays. The chimeric chemokine receptor can also form a component of a chemokine receptor modulator design program.

Polynucleotides encoding chimeric chemokine receptors

Growing community of inventors

Media, PA, United States of America

Peggy Ann Scherle